New products will drive glaucoma market's 4.1% CAGR by 2026

The total glaucoma market was estimated to be $2.6 billion across the seven major markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan) in 2016. This is expected to grow to $3.8 billion in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to data and analytics company GlobalData.

The company’s latest report: ‘PharmaPoint: Glaucoma’ revealed that this growth will be driven by the launch of pipeline products. GlobalData anticipates that five products in the late-stage pipeline will enter the glaucoma market during the forecast period. These products include a first-in-class drug Santen’s DE-117 (omidenepag isopropyl) as well as one drug with an undisclosed MOA. Aerie Pharmaceuticals’ (Nasdaq: AERI) fixed-dose combination therapy, Roclatan (netarsudil/latanoprost ophthalmic solution), and two sustained-release (SR) implants are also set to launch during the forecast period.

Thomas Moore, healthcare analyst at GlobalData, comments: “The late-stage pipeline drugs are set to have a significant impact on the glaucoma market, and be a key driver of growth throughout the forecast period. GlobalData forecasts that two pipeline products, Aerie’s Roclatan and Allergan’s [NYSE: AGN] bimatoprost SR, will become the most successful drugs in the glaucoma market, with sales of $631.9 million and $609.5 million, respectively. Overall, GlobalData predicts that drugs that launch during the forecast period will account for 41% of the global glaucoma market in 2026.”